American Journal of Pharmacological Sciences
ISSN (Print): 2327-6711 ISSN (Online): 2327-672X Website: http://www.sciepub.com/journal/ajps Editor-in-chief: Srinivas NAMMI
Open Access
Journal Browser
Go
American Journal of Pharmacological Sciences. 2014, 2(5), 87-92
DOI: 10.12691/ajps-2-5-3
Open AccessArticle

Evaluation of Fetuin-A Protein and Some Inflammatory Biomarkers in Patients with Coronary Artery Disease

Amal M. Hassan1, , Eman S. Saleh1 and Sarkis K. Strak2

1Department of Clinical Laboratory Sciences, College Of Pharmacy, University Of Baghdad/ Baghdad/Iraq

2Department of Medicine, College Of Medicine, University Of Basra/ Basra/Iraq

Pub. Date: November 02, 2014

Cite this paper:
Amal M. Hassan, Eman S. Saleh and Sarkis K. Strak. Evaluation of Fetuin-A Protein and Some Inflammatory Biomarkers in Patients with Coronary Artery Disease. American Journal of Pharmacological Sciences. 2014; 2(5):87-92. doi: 10.12691/ajps-2-5-3

Abstract

Background and Objectives: Coronary artery disease (CAD) is a state of insufficient supply of oxygenated blood to a part of myocardium. The most common cause of myocardial ischemia is atherosclerosis. Inflammation plays an important role in atherosclerosis and hence CAD. The principle inflammatory markers that believed to have a key position in the pathogenesis of CAD include fetuin-A protein, high sensitive C-reactive protein (hs-CRP), tumor necrosis factor-alpha (TNF-α), and soluble intracellular adhesion molecule-one (sICAM-1). The aim of study was carried out to evaluate fetuin-A protein and some inflammatory biomarkers in patients with coronary artery disease. Subjects and Methods: Ninety subjects above forty year old; (45) patients with acute coronary syndrome (ACS); were divided in three groups: Unstable angina (UA), non-ST- elevation myocardial infarction (NSTEMI), and ST-elevation myocardial infarction (STEMI), all selected from Coronary Care Unit (CCU), and (45) apparently healthy age and sex matched subjects as controls. Five milliliters (5ml) of venous blood sample were drawn from each patient and healthy persons (controls), centrifuged to obtain serum, to be used for measuring the following variables: Fetuin-A protein, hs-CRP, TNF-α, sICAM-1. Results: Fetuin-A protein was significantly lower, while hs-CRP, TNF- α, and sICAM-1 were higher in patients. A low Fetuin-A protein level was inversely associated with increasing age. A high TNF- α level wasassociated with increased BMI. Conclusions: Lower serum Fetuin-A level, and higher serum levels of hs-CRP, TNF- α, and sICAM-1 are associated with ACS. The future may be promising in rising of anew tests that use for evaluation of patients with suspected ACS.

Keywords:
coronary artery disease fetuin-A hs-CRP TNF-α sICAM-1

Creative CommonsThis work is licensed under a Creative Commons Attribution 4.0 International License. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/

References:

[1]  Hamm C., Agewall S., Bax J., Boersma E., Dudek D., Ohman M., et al.:ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation, European Heart Journal, 2011; 32: 2999-3054.
 
[2]  Silvaa D., and de Lacerda A.: High-sensitivity C-reactive protein as a biomarker of risk in coronary artery disease, Revista Portuguesa de Cardiologia, 2012; 31(11):733-45.
 
[3]  Cubukcuoglu T., Rasschaert N., Kacan C., Gul C. and Yavuz M.: Relationship between fetuin-A level and cardiovascular risk factors in peritoneal dialysis patients, Turkish Nephrology Dialysis and Transplantation Journal,2013; 22 (1): 78-9.
 
[4]  Heiss A., Schwarz A., Westenfeld R., Ketteler M., Floege J., Schinke T., et al.: The serum protein α2–Heremans-Schmid glycoprotein/fetuin-A is a systemically acting inhibitor of ectopic calcification, The Journal of Clinical Investigation, 2003; 112 (3): 357-66.
 
[5]  Pateinakis P., Papagianni A., Douma S., Efstratiadis G. and Memmos D.: Associations of fetuin-A and osteoprotegerin with arterial stiffness and early atherosclerosis in chronic hemodialysis patients, BMC Nephrology Journal, 2013; 14: 122.
 
[6]  Gangneux C., Daveau M., Hiron M., Derambure C., Papaconstantinou J. and Salier J.: The inflammation induced down regulation of plasma fetuin-A (α2HS-glycoprotein) in liver results from the loss of interaction between long C/EBP isoforms at two neighboring binding sites, Nucleic Acid Research Journal, 2003; 31(20): 5957-70.
 
[7]  Barrett-Connor E., Wassel C., Cummins K., Bergstrom J., Daniels L. and Laughlin G.: The associations of fetuin-A with subclinical cardiovascular disease in community-dwelling persons: the Rancho Bernardo Study, Journal of American College of Cardiology (JACC), 2011; 58 (23): 2372-79.
 
[8]  Napoli M.: Elkind M., Godoy D., Singh P., Papa F., Popa-Wagner A., et al. Role of C-reactive protein in cerebrovascular disease, Expert Review Cardiovascular Therapy, 2011; 9 (12): 1565-84.
 
[9]  Jialal I. and Devaraj S.: Inflammation and atherosclerosis the value of the high-sensitivity C-reactive protein assay as a risk marker, American Journal of Clinical Pathology, 2001; 116: 108-15.
 
[10]  Sheikh A., Yahya S., Sheikh N., and Sheikh N.: C-reactive protein as a predictor of adverse outcome in patients with acute coronary syndrome, Heart Views, 2012; 13(1): 7-12.
 
[11]  Tintut Y., Patel J., Parhami F. and Demer L.: Tumor necrosis factor-alpha promotes in vitro calcification of vascular cells via the cAMP pathway, Circulation, 2000; 102(21): 2636-42.
 
[12]  Padfield G., Din J., Koushiappi E., Mills N. and Newby D.: Cardiovascular effects of tumor necrosis factor α antagonism in patients with acute myocardial infarction: Afirst in human study, British Medical Journal (BMJ), 2013; 99: 1330-35.
 
[13]  Yang Y., Jun C., Liu J., Zhang R., Joachimiak A., Springer T.,et al.: Structural basis for dimerization of ICAM-1 on the cell surface, Molecular Cell journal, 2004;14: 269-76.
 
[14]  Shaker O., Zahra A., Sayed A., Refaat A., El-Khaiat Z., Hegazy G., et al.: Role of ICAM-1 and E-selectin gene polymorphisms in pathogenesis of PAOD in Egyptian patients, Vascular Health and Risk Management, 2010: 6 : 9-15.
 
[15]  Lu H., Sheng Z., Wang Y. andZhang L.: Levels of soluble adhesion molecules in patients with various clinical presentations of coronaryatherosclerosis, Chines Medical Journal (Engl). 2010; 123 (21): 3123-6.
 
[16]  Ix J., Biggs M., Mukamal K., Kizer J., Zieman S., Siscovick D., et al.: Association of fetuin-a with incident diabetes mellitus in community living older adults: the cardiovascular health Study, Circulation, 2012;125(19): 2316-22.
 
[17]  Mitra B. and Panja M.: High sensitive C-reactive protein: A novel biochemical markers and its role in coronary artery disease, The Journal of the Association of Physicians of India, 2005; 53: 25-32.
 
[18]  De Totero D., Tazzari P., Capaia M., Montera M., Clavio M., Balleari E., et al.: CD40 triggering enhances fludarabine-induced apoptosis of chronic lymphocytic leukemia B-cells through autocrine release of tumor necrosis factor-alpha and interferon-gama and tumor necrosis factor receptor-I-II upregulation, Haematologica, 2003 ;88(2): 148-58.
 
[19]  Postadzhiyan A., Tzontcheva A., Kehayov I. and Finkov B.: Circulating soluble adhesion molecules ICAM-1 and VCAM-1 and their association with clinical outcome, troponin T and C-reactive protein in patients with acute coronary syndromes, Clinical Biochemistry, 2008; 41(3): 126-33.
 
[20]  "BMI Classification". Global Database on Body Mass Index. World Health Organization. 2006. Retrieved July 27, 2012.
 
[21]  Lim P., Moutereau S., Simon T., Gallet R., Probst V., Ferrieres J., et al.Usefulness of Fetuin-A and C-Reactive Protein Concentrations for Prediction of Outcome in Acute Coronary Syndromes (from the French Registry of Acute ST-Elevation Non-ST-Elevation Myocardial Infarction [FAST-MI]), The American Journal of Cardiology, 2013;111(1): 31-7.
 
[22]  Reynolds J., Skepper J., McNair R., Kasama T., Gupta K., Weissberg P., et al.: Multifunctional roles for serum protein fetuin-a in inhibition of human vascular smooth muscle cell calcification, Journal of American Society of Nephrology, 2005;16(10): 2920-30.
 
[23]  Afsar C., Yurdaku S., Muderrisoglu C., Demir B., Aslan A., Aral H., et al.: Association of serum fetuin-A levels with heart valve calcification and other biomarkers of inflammation among persons with acute coronary syndrome, Clinical and Investigative Medicine, 2012; 35 (4): 206-15.
 
[24]  Bilgir O., Kebapcilar L., Bilgir F., Bozkaya G., and Yildiz Y., Pinar P., et al:Decreased Serum Fetuin-A Levels are Associated with Coronary Artery Diseases, Internal Medicine, 2010; 49: 1281-85.
 
[25]  Steyers C., and Miller F.: Endothelial Dysfunction in Chronic Inflammatory Diseases, International Journal of Molecular Science, 2014; 15(7): 11324-49.
 
[26]  Rajappa M, Sen SK., and Sharma A.: Role of pro-/anti-inflammatory cytokines and their correlation with established risk factors in South Indians with coronary artery disease, Angiology, 2009; 60(4): 419-26.
 
[27]  Swaroop J., Rajarajeswari D., and Naidu J.: Association of TNF-α with insulin resistance in type 2 diabetesmellitus, Indian Journal of Medical Research, 2012; 135: 127-130.
 
[28]  Peng D., Zhao S., Li Y., Li J. andZhou H.: Elevated soluble CD40 ligand is related to the endothelial adhesion molecules in patients with acute coronary syndrome, International Journal of Clinical Chemistry, 2002; 319(1): 19-26.
 
[29]  Bossowska A., Kiersnowska-Rogowska B.,Bossowski A., Galar B. and Sowiński P.: Assessment of serum levels of adhesion molecules (sICAM-1, sVCAM-1, sE-selectin) in stable and unstable angina and acute myocardial infarction, PrzegladLekarski, 2003; 60(7):445-50.